CTI Biopharma Corp expected to post a loss of 12 cents a share - Earnings Preview

CTI Biopharma

10/05/2023 03:03

* CTI Biopharma Corp  CTIC.OQ   CTIC.O  is expected to show
a rise
in quarterly revenue when it reports  results on May 11. 
    * The Seattle Washington-based  company is expected to
report  a
899.9% increase in revenue to $22.948 million from $2.3 million
a year ago, according to the mean estimate from 9 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for CTI Biopharma Corp
is for
a loss of 12 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 3.6%
in the last three months. ​
    * Wall Street's median 12-month price target for CTI
Biopharma
Corp is $11​, above​ its last closing price of $4.82. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.10       -0.10      -0.14     Missed  -44.8
 Sep. 30 2022  -0.16       -0.16      -0.13     Beat    17
 Jun. 30 2022  -0.20       -0.20      -0.21     Missed  -4.3​
 Mar. 31 2022  -0.45       -0.41      -0.37     Beat    10.6
 ​​Dec.        -0.28       -0.28      -0.38     Missed  -34.9
 31 2021                                                
 Sep. 30 2021  -0.22       -0.25      -0.26     Missed  -4.7​
 Jun. 30 2021  -0.21       -0.21      -0.21     Met     0
 Mar. 31 2021  -0.22       -0.22      -0.23     Missed  -5.7
 This summary was machine generated May 10 at 02:02 GMT.  All
figures in US dollars  unless otherwise stated